Off-label use of duct occluder devices to close hemodynamically significant perimembranous ventricular septal defects: A multicenter experience.


Journal

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139

Informations de publication

Date de publication:
01 01 2019
Historique:
received: 24 02 2018
revised: 15 06 2018
accepted: 20 06 2018
pubmed: 13 9 2018
medline: 21 1 2020
entrez: 13 9 2018
Statut: ppublish

Résumé

We sought to evaluate the feasibility, technical aspects, and outcome of transcatheter perimembranous ventricular septal defect (pmVSD) closure using duct occluder devices with a single retention disc. Use of duct occluder devices to close pmVSD seems a promising alternative therapy. However, limited data exist on this technique. From 2010 to 2016, 222 patients (female 47.7%) were identified from databases of five participating institutions in whom pmVSD closure was attempted using an Amplatzer Duct Occluder I or Lifetech duct occluder device. Patients ranged in age from 0.7 to 52 years (median, 7.0 years) and in weight from 4.0 to 70 kg (median, 18.0 kg). The mean size of the VSD was 6.8 ± 2.2 mm. A large defect (> 6 mm) was present in 137 patients (61.7%). Device closure was successful in 218 patients (98.2%). The 10/8 mm device was used in most patients (n = 85, 38.3%), and the vascular approach was from the femoral vein in 169 patients (76.1%). There were 18 early complications in 17/218 patients (7.8%). Three patients (1.4%) developed complete heart block (transient n = 2; requiring permanent pacing n = 1). Median follow-up was 6 months (6 months-6 years). A mild residual shunt was seen in 10 patients at 6 months follow-up. The immediate results of transcatheter pmVSD closure using a duct occluder device with a single retention disc are promising. It is an effective technique with a lower rate of complications than for other currently available devices.

Sections du résumé

OBJECTIVE
We sought to evaluate the feasibility, technical aspects, and outcome of transcatheter perimembranous ventricular septal defect (pmVSD) closure using duct occluder devices with a single retention disc.
BACKGROUND
Use of duct occluder devices to close pmVSD seems a promising alternative therapy. However, limited data exist on this technique.
METHODS
From 2010 to 2016, 222 patients (female 47.7%) were identified from databases of five participating institutions in whom pmVSD closure was attempted using an Amplatzer Duct Occluder I or Lifetech duct occluder device.
RESULTS
Patients ranged in age from 0.7 to 52 years (median, 7.0 years) and in weight from 4.0 to 70 kg (median, 18.0 kg). The mean size of the VSD was 6.8 ± 2.2 mm. A large defect (> 6 mm) was present in 137 patients (61.7%). Device closure was successful in 218 patients (98.2%). The 10/8 mm device was used in most patients (n = 85, 38.3%), and the vascular approach was from the femoral vein in 169 patients (76.1%). There were 18 early complications in 17/218 patients (7.8%). Three patients (1.4%) developed complete heart block (transient n = 2; requiring permanent pacing n = 1). Median follow-up was 6 months (6 months-6 years). A mild residual shunt was seen in 10 patients at 6 months follow-up.
CONCLUSIONS
The immediate results of transcatheter pmVSD closure using a duct occluder device with a single retention disc are promising. It is an effective technique with a lower rate of complications than for other currently available devices.

Identifiants

pubmed: 30208249
doi: 10.1002/ccd.27792
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

82-88

Informations de copyright

© 2018 Wiley Periodicals, Inc.

Auteurs

Floris E A Udink Ten Cate (FEA)

Department of Pediatric Cardiology, Heart Center Cologne, University Hospital of Cologne, Cologne, Germany.
Department of Pediatric Cardiology, Amalia Children's Hospital, Radboud University Medical Center, Nijmegen, The Netherlands.

Rodina Sobhy (R)

Department of Pediatric Cardiology, Cairo University Children's Hospital, Cairo, Egypt.

Atul Kalantre (A)

Department of Pediatric Cardiology, Amrita Institute of Medical Sciences, Kochi, India.

Sakshi Sachdev (S)

Department of Pediatric Cardiology, CARE Hospital, Hyderabad, India.

Anand Subramanian (A)

Sri Jayadeva Institute of Cardiovascular Sciences and Research, Bengaluru, India.

Nageswara Rao Koneti (NR)

Department of Pediatric Cardiology, CARE Hospital, Hyderabad, India.

Raman Krishna Kumar (RK)

Department of Pediatric Cardiology, Amrita Institute of Medical Sciences, Kochi, India.

Hala Hamza (H)

Department of Pediatric Cardiology, Cairo University Children's Hospital, Cairo, Egypt.

Mahimarangaiah Jayranganath (M)

Sri Jayadeva Institute of Cardiovascular Sciences and Research, Bengaluru, India.

Narayanswami Sreeram (N)

Department of Pediatric Cardiology, Heart Center Cologne, University Hospital of Cologne, Cologne, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH